How MiNK stole the NK T show
A single but durable stable disease sends the microcap's stock up 730%.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
